# Small organisms, big returns

> Shared infrastructure for model-organism research would multiply the value of India’s new research investments.

Source: https://khushisingh.in/policy/briefs/small-organisms-big-returns/
Author: Khushi Singh (khushisingh.in). Licence: CC BY 4.0 for text and original illustrations, unless a credit says otherwise.
Evidence labels used on this site: established, strong evidence, emerging, hypothesis, debated. Where a page has Simple, Curious and Expert versions, all three follow.

---

[Policy brief](https://khushisingh.in/policy/) · v0.9 · 3 October 2026

Draft for expert review: not yet externally reviewed

**For:** ANRF · DST · DBT / BIRAC (BioE3) · Office of the Principal Scientific Adviser · NITI Aayog

## Key messages

1. Small model organisms (fruit flies, worms, yeast, zebrafish) make basic discoveries fast and cheaply: of 929 human disease genes checked, 77% have a fruit-fly counterpart. (high confidence)
2. India’s research investment is rising (R&D at 0.84% of GDP in 2023–24; ANRF; the ₹1 lakh crore RDI scheme; BioE3), creating a window to fund shared infrastructure. (very high confidence)
3. Shared resource centres, imaging cores and open-data requirements multiply returns on individual grants and widen access beyond a few elite institutions. (medium confidence)

## What this means for policy

- Fund national model-organism resource centres (stocks, reagents, training) that any Indian lab can use.
- Create regional shared microscopy and imaging cores with trained staff and open booking.
- Require open protocols and data from publicly funded projects, and back early-career and international-exchange schemes.

## The issue

Many medical breakthroughs began in “simple” organisms:

- the genes that build an embryo were found in flies (Nobel Prize 1995);
- the innate-immunity switch was found in flies (Nobel 2011);
- the body clock was found in flies (Nobel 2017);
- autophagy was worked out in yeast (Nobel 2016).

These organisms are cheap to keep and quick to breed, and they come with powerful genetic tools. But productive research needs **shared infrastructure**: stock centres, reagents, microscopes and trained staff. Few labs can afford these alone.

## India’s moment

| Indicator | Value |
| --- | --- |
| Gross R&D spending | ₹2.45 lakh crore, **0.84% of GDP** (2023–24, all-time high) |
| Full-time-equivalent researchers | about 5.07 lakh (354 per million people) |
| Women among researchers | **29%** (2023–24), up from 18.6% (2020–21) |
| New funding instruments | ANRF (in force February 2024); RDI scheme (₹1 lakh crore corpus, 2025); BioE3 policy (2024); One Nation One Subscription (2025) |
| International links | 78 Max Planck partner groups in India since 2004; about 1 in 12 Max Planck doctoral researchers was Indian (2022); IGSTC joint programmes |

## What science knows

- **Shared biology:** most known human disease genes have fly counterparts (77% of 929 searched; other estimates about 65%). (evidence: strong evidence)
- **Speed and cost:** a fruit-fly generation takes about 10 days, and flies need only simple food and space. (evidence: established)
- **Infrastructure multiplies output:** stock centres and core facilities let many groups share expensive resources. International stock centres have long underpinned fly research worldwide. (evidence: strong evidence)
- **Openness raises trust and reuse:** studies using open practices are rated as more credible by the public. (evidence: emerging)

## Options

| Option | Benefit | Cost / feasibility | Risk | Evidence |
| --- | --- | --- | --- | --- |
| National model-organism resource centres (stocks, reagents, training) | Lowers entry barriers for every lab | Moderate, recurring | Needs stable long-term funding | Strong |
| Regional shared imaging cores with staff scientists | Access to advanced microscopy beyond elite institutes | High capital; moderate running | Under-use without training | Strong |
| Open-protocol and open-data requirements for public grants | Reuse, reproducibility, trust | Low | Compliance burden | Medium |
| Early-career grants and exchange (ANRF early-career schemes, IGSTC, Max Planck partner groups) | Retains and grows talent, including women | Moderate | Brain drain without return paths | Medium |

## Research needed

Which shared facilities yield the most research per rupee in India? How can access be widened beyond metropolitan institutes, for example through regional hubs or travel grants?

## Method

A non-systematic synthesis of official statistics and policy documents with peer-reviewed literature (searched October 2026). The author is an early-career researcher trained in fruit-fly biology; this is a disclosed interest. External expert review is pending.

## References

1. Reiter LT, et al. (2001) A systematic analysis of human disease-associated gene sequences in Drosophila melanogaster. Genome Research 11:1114–1125. [doi:10.1101/gr.169101](https://doi.org/10.1101/gr.169101)
2. Ugur B, Chen K, Bellen HJ (2016) Drosophila tools and assays for the study of human diseases. Disease Models & Mechanisms 9:235–244. [doi:10.1242/dmm.023762](https://doi.org/10.1242/dmm.023762)
3. Department of Science and Technology (2026) Research & Development Statistics at a Glance 2025–26. [link](https://dst.gov.in/)
4. Anusandhan National Research Foundation (ANRF) Act, 2023; Research, Development and Innovation (RDI) scheme, 2025; BioE3 policy, 2024 (Government of India). [link](https://anrfonline.in/)
5. Max Planck Society: Max Planck in India (partner groups and doctoral researchers). [link](https://www.mpg.de/india)
6. Indo-German Science & Technology Centre (IGSTC). [link](https://www.igstc.org/)

**How to cite:** Singh K. (2026). Small organisms, big returns. khushisingh.in policy brief, version 0.9. https://khushisingh.in/policy/briefs/small-organisms-big-returns/

**Disclaimer:** Personal views of the author, a student researcher. Not the position of the Max Planck Institute of Immunobiology and Epigenetics, IISER Pune or any funder. Evidence syntheses from published sources; no unpublished data. Not medical advice.

**Confidence levels** follow a simplified IPCC-style scale combining the amount of evidence and the agreement between studies. See [how we work](https://khushisingh.in/policy/how-we-work/).